Phenotype of SARS-CoV-2-specific T-cells in COVID-19

patients with acute respiratory distress syndrome

- 4 Daniela Weiskopf^{1#}, Katharina S. Schmitz^{2#}, Matthijs P. Raadsen², Alba Grifoni¹, Nisreen M.A. Okba²,
- 5 Henrik Endeman³, Johannes P.C. van den Akker³, Richard Molenkamp², Marion P.G. Koopmans²,
- 6 Eric C.M. van Gorp², Bart L. Haagmans², Rik L. de Swart², Alessandro Sette^{1,4,5\$} & Rory D. de
- 7 *Vries*²**
- 9 ¹ Center for Infectious Disease, La Jolla Institute for Immunology, La Jolla, CA92037, USA
- 10 ² Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
- 11 ³ Department of Intensive Care, Erasmus MC, Rotterdam, the Netherlands
- 12 ⁴ Department of Pathology, University of California, San Diego, CA92037, USA
- 13 Department of Medicine, University of California, San Diego, CA92037, USA
- 15 # equal first author contribution

1

2

3

8

14

18

- 16 s equal last author contribution
- 17 * author for correspondence: <u>r.d.devries@erasmusmc.nl</u>
- 19 **Running title:** SARS-CoV-2-specific T-cells in ARDS patients

21 **Summary** 22 COVID-19 is associated with lymphopenia and 'cytokine storm', but there is a 23 scarcity of information on specific cellular immune responses to SARS-CoV-2. Here, we characterized SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells in patients 24 25 hospitalized with acute respiratory distress syndrome (ARDS). 26 27 **Abstract** 28 SARS-CoV-2 has been identified as the causative agent of a global outbreak of 29 respiratory tract disease (COVID-19). In some patients the infection results in 30 moderate to severe acute respiratory distress syndrome (ARDS), requiring invasive 31 mechanical ventilation. High serum levels of IL-6 and an immune 32 hyperresponsiveness referred to as a 'cytokine storm' have been associated with poor clinical outcome. Despite the large numbers of cases and deaths, information 33 34 on the phenotype of SARS-CoV-2-specific T-cells is scarce. Here, we detected 35 SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells in 100% and 80% of COVID-19 36 patients, respectively. We also detected low levels of SARS-CoV-2-reactive T-cells 37 in 20% of the healthy controls, not previously exposed to SARS-CoV-2 and indicative 38 of cross-reactivity due to infection with 'common cold' coronaviruses. Strongest Tcell responses were directed to the surface glycoprotein (spike, S), and SARS-CoV-39 40 2-specific T-cells predominantly produced effector and Th1 cytokines, although Th2 41 and Th17 cytokines were also detected. Collectively, these data stimulate further 42 studies into the role of T-cells in COVID-19, support vaccine design and facilitate the 43 evaluation of vaccine candidate immunogenicity.

Introduction

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

A novel coronavirus, named SARS-CoV-2, has been identified as the causative agent of a global outbreak of respiratory tract disease, referred to as COVID-19 (Chan et al., 2020; Huang et al., 2020). On May 1st, over 3 million cases and more than 230,000 deaths were reported globally. COVID-19 is characterized by fever, cough, dyspnea and myalgia (Huang et al., 2020), but in some patients the infection results in moderate to severe acute respiratory distress syndrome (ARDS), requiring invasive mechanical ventilation for a period of several weeks. COVID-19 patients may present with lymphopenia (Chen et al., 2020; Huang et al., 2020), but the disease has also been associated with immune hyperresponsiveness referred to as a 'cytokine storm' (Mehta et al., 2020). A transient increase in co-expression of CD38 and HLA-DR by T-cells, a phenotype of CD8⁺ T-cell activation in response to viral infection, was observed concomitantly (Xu et al., 2020). This increase in both CD4+ and CD8⁺ CD38⁺HLA-DR⁺ T-cells preceded resolution of clinical symptoms in a nonsevere, recovered, COVID-19 patient (Thevarajan et al., 2020). Despite the large numbers of cases and deaths, there is a scarcity of information on the phenotype of SARS-CoV-2-specific T-cells. Spike surface glycoprotein (S-), Mand NP-specific T-cells were detected in PBMC from convalescent COVID-19 patients (Ni et al., 2020). Virus-specific T-cells have also been detected after exposure to the related SARS-CoV and MERS-CoV, although few studies have characterized cellular responses in human patients. For SARS-CoV-specific CD4⁺ Tcells it was reported that the S glycoprotein accounted for nearly two thirds of T-cell reactivity, N and M also accounted for limited reactivity (Li et al., 2008). For MERS-

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

CoV-specific CD4⁺ T-cells responses targeting S, N and a pool of M and E peptides have been reported (Zhao et al., 2017). Here, we stimulated peripheral blood mononuclear cells (PBMC) from ten COVID-19 patients with ARDS, collected up to three weeks after admission to the intensive care unit (ICU), with MegaPools (MP) of overlapping or prediction-based peptides covering the SARS-CoV-2 proteome (Grifoni et al., 2020). We detected SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells in 10/10 and 8/10 COVID-19 patients, respectively. Peptide stimulation of healthy control (HC) PBMC samples collected before the outbreak in most cases resulted in undetectable responses, although some potential cross-reactivity due to infection with 'common cold' coronaviruses was observed. SARS-CoV-2-specific T-cells predominantly produced effector and Th1 cytokines, although Th2 and Th17 cytokines were also detected. **Results & Discussion** We included ten COVID-19 patients with moderate to severe ARDS in this study. All patients were included in the study shortly after ICU admission; self-reported illness varied between 5 and 14 days before inclusion (Figure 1a). Patients were between 49 and 72 years old (average 58.9 ± 7.2 years) and of mixed gender (4 female, 6 male). All patients tested SARS-CoV-2 positive by RT-PCR and were ventilated during their stay at the ICU. At the time of writing, 5 patients were transferred out of the ICU (case 1, 2, 4, 6 and 7), 3 patients were still in follow-up (case 5, 9 and 10), 1 patient was discharged (case 8) and 1 patient was deceased (case 3). Case 4 was deceased 4 days after transfer out of the ICU. Patients were treated with lung protective ventilation using the higher PEEP/lower FiO₂ table of the ARDSnet and

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

restrictive volume resuscitation. They received antibiotics as a part of a treatment regimen aimed at selective decontamination of the digestive tract. Furthermore, all patients received chloroquine, lopinavir, ritonavir and / or corticosteroids for a brief period of time around admission to the ICU (Figure 1a). Phenotyping analysis of PBMC collected 14 days post inclusion via flow cytometry indicated that COVID-19 patients presented with low percentages of CD3⁺ T-cells in peripheral blood, corresponding to the previously reported lymphopenia (12.1 ± 8.7%) in COVID-19 vs $44.3 \pm 7.1\%$ in HC, p < 0.0001, Figure 1b) (Chen et al., 2020; Huang et al., 2020). CD4:CD8 ratios were increased in COVID-19 patients when compared to HC (5.5 \pm 3.0 in COVID-19 vs 2.3 \pm 0.9 in HC, p=0.0106, Figure 1c). PBMC from COVID-19 ARDS patients were stimulated with three different peptide MPs: MP S, MP CD4 R and two MP CD8 pools. MP S contained 221 overlapping peptides (15-mers overlapping by 10 amino acids) covering the entire S glycoprotein and can stimulate both CD4+ and CD8+ T-cells. MP CD4 R contained 246 HLA class II predicted epitopes covering all viral proteins except S, specifically designed to activate CD4⁺ T-cells. The two MP CD8 pools combined contained 628 HLA class I predicted epitopes covering all SARS-CoV-2 proteins, specifically designed to activate CD8⁺ T-cells (Grifoni et al., 2020). Results obtained with MP CD8 A and MP CD8 B have been concatenated and shown as a single stimulation in Figure 2, results obtained with separate stimuli are shown in Supplementary Figure 2. In addition to stimulation of PBMC from COVID-19 ARDS patients, ten HC were included in this study as negative controls. PBMC from healthy controls were obtained before 2020 and could therefore not contain SARS-CoV-2-specific T-cells,

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

however they potentially contain cross-reactive T-cells induced by circulating seasonal 'common cold' coronaviruses (Kissler et al., 2020). Stimulation of PBMC collected 14 days post inclusion with the different peptide pools led to consistent detection of CD4⁺ and / or CD8⁺ SARS-CoV-2-specific T-cells in COVID-19 ARDS patients (Figure 2, Supplementary Figure 2 and Table 1). Specific activation of CD4⁺ and CD8⁺ T-cells was measured via cell surface expression of CD69 and CD137; phenotyping of memory subsets was based on surface expression of CD45RA and CCR7 (Supplementary Figure 1). Stimulation of PBMC with MP S and MP CD4 R led to consistent activation of SARS-CoV-2-specific CD4⁺ T-cells (Figure 2a and b) in PBMC obtained from COVID-19 ARDS patients. Significant responses were detected when activation percentages after stimulation with MP S and MP CD4 R were compared with the vehicle control (DMSO). To allow comparison between HC and COVID-19 ARDS patients, we corrected the MP-specific activation percentages by subtracting the value obtained in the DMSO stimulation. Significant T-cell responses were observed in COVID-19 ARDS patients when compared with HC (0.64% in COVID-19 vs 0.02% in HC, p<0.0001 for MP S and 0.29% in COVID-19 vs 0.02% in HC, p=0.0002 for MP CD4 R, Figure 2a). The stimulation index (SI) was calculated by dividing the MP-specific responses by the DMSO responses (Supplementary Figure 2a), and donors with a SI > 3 were regarded responders (Table 1). According to this definition all COVID-19 ARDS patients responded to the MP S and MP CD4 R pools, whereas only 1/10 and 2/10 of the HC responded, respectively. Overall, the MP S peptide pool induced stronger responses than the MP CD4 R peptide pool,

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

indicating that the S glycoprotein is a strong inducer of CD4⁺ T-cell responses. Phenotyping of CD4⁺CD69⁺CD137⁺ activated T-cells identified the majority of these SARS-CoV-2-specific T-cells as central memory T-cells, based on CD45RA and CCR7 expression (T^{CM}). T^{CM} express homing receptors required for extravasation and migration to secondary lymphoid tissues, but also have high proliferative capacity with low dependence on co-stimulation (Mahnke et al., 2013; Sallusto et al., 1999). SARS-CoV-2-specific CD8⁺ T-cells were activated by both the MP S and MP CD8 peptide pools when compared to vehicle control (Figure 2c and d). Furthermore, significant responses were detected when activation percentages after stimulation with MP S and MP CD8 were compared between HC controls and COVID-19 ARDS patients after DMSO correction (0.90% in COVID-19 vs 0.03% in HC, p=0.0003 for MP S and 0.57% in COVID-19 vs 0.03% in HC, p<0.0001 for MP CD8, Figure 2b). In addition to inducing specific CD4⁺ T-cells, the S glycoprotein also induced CD8⁺ T-cell responses. Calculation of the SI identified 8/10 and 4/9 of the COVID-19 ARDS patients as responders to MP S and MP CD8, respectively, whereas 1/10 of the HC responded to the MP_S stimulation (Supplementary Figure 2, Table 1). Phenotyping of CD8⁺CD69⁺CD137⁺ activated T-cells showed that these had a mixed phenotype. The majority of virus-specific CD8⁺ T-cells was identified as CCR7⁻ effector memory (T^{EM}) or terminally differentiated effector (T^{EMRA}) (Mahnke et al., 2013). Both these CD8⁺ effector subsets are potent producers of IFN_γ, contain preformed perforin granules for immediate antigen-specific cytotoxicity and home efficiently to peripheral lymphoid tissues (Sallusto et al., 1999).

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

As production of pro-inflammatory cytokines can be predictive of clinical outcome for other viral diseases (Wang et al., 2014), we measured antigen-specific production of 13 cytokines in cell culture supernatants from PBMC after stimulation. PBMC were stimulated with the respective peptide pools, cytokine production after MP S stimulation is shown in Figure 3 and Supplementary Figure 3 as representative data (data for other stimulations not shown). When compared to the vehicle control stimulation, PBMC obtained from COVID-19 ARDS patients specifically produced IFN_γ, TNFα, IL-2, IL-5, IL-13, IL-10, IL-9, IL-17a, IL-17f and IL-22 after MP S stimulation (Figure 3, Supplementary Figure 3). When comparing COVID-19 ARDS patients with HC, stimulation of PBMC by the overlapping S peptide pool led to a strong significant production of the Th1 or effector cytokines IFN γ , TNF α and IL-2 in COVID-19 ARDS patients. More characteristic Th2 cytokines (IL-5, IL-13, IL-9 and IL-10) were also consistently detected, albeit at low levels. IL-4 and IL-21 could not be detected at all. IL-6 levels were not different between COVID-19 patients and HC, however results were difficult to interpret because mock stimulation already resulted in high IL-6 expression. Antigen-specific production of cytokines related to a Th17 response was mixed; PBMC from COVID-19 ARDS patients produced significantly more IL-17a and IL-22 than HC; this was not observed for IL-17f. In general, stimulation of PBMC from COVID-19 ARDS patients with MP led to a dominant production Th1 or effector cytokines (IFN_γ, TNFα, IL-2), but Th2 (IL-5, IL-13, IL-9, IL-10) and Th17 cytokines could also be detected (IL-17a, IL-17f and IL-22). Although not enough COVID-19 ARDS patients were included in this study to

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

correlate specific T-cell responses to clinical outcome, we did observe differences in cytokine production profiles on a case-per-case basis (Supplementary Figure 3d). Plotting the respective cytokine quantities as a percentage of total cytokine production showed that either IL-6 (case 3, 5 and 9), TNF α (case 1, 3 and 9), IL-2 (case 8) or IFNy (case 2, 4, 6, 7 and 10) dominated the response. Finally, we studied the kinetics of development of virus-specific humoral and cellular immune response in eight COVID-19 ARDS patients included in this study (case 1 – 8). Real time RT-PCR detection of SARS-CoV-2 genomes in respiratory tract samples showed a decreasing trend over time (Figure 4a, ANOVA repeated measures p<0.001), whereas virus-specific serum IqG antibody levels, measured by RBD ELISA, showed a significant increase (Figure 4b, ANOVA repeated measures, p<0.001). Concomitantly, SARS-CoV-2-specific T-cells were detected in all patients at multiple time-points and frequencies of virus-specific responder cells increased significantly over time (Figure 4c, ANOVA repeated measures, p<0.001). Collectively, these data provide information on the phenotype, breadth and kinetics of virus-specific cellular immune responses in COVID-19 ARDS patients. We provide evidence that SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells appear in blood of ARDS patients in the first two weeks post onset of symptoms, and their frequency increases over time. SARS-CoV-2-specific CD4+ T-cells in blood typically had a central memory phenotype, whereas CD8⁺ T-cells had a more effector phenotype. Consistent production in response to viral antigen of IFNγ, TNFα, IL-2, IL-5, IL-13, IL-9, IL-10, IL-17a, IL-17f and IL-22 was observed, with a dominant production of the effector and Th1 cytokines. Due to limitations in the number of PBMC that could be

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

obtained from severe COVID-19 ARDS patients in an ICU setting, we could not resolve which cells were responsible for production of which cytokine by intracellular cytokine staining. Elevated levels of IL-6 in patient plasma have been correlated to respiratory failure in COVID-19 patients (Herold et al., 2020). Although we could not detect increased specific production of IL-6 in PBMC stimulated with peptide pools due high background production in controls (potentially due to in vivo activation), we detected a dominant IL-6 and TNF α response in cell culture supernatants from the patient deceased due to respiratory failure (case 3). To determine the role of T-cells in COVID-19, it is crucial that the cell types responsible for the production of IL-6 and the concomitant 'cytokine storm' are identified in large comparative cohort studies. We included PBMC obtained from ten buffycoats obtained before the SARS-CoV-2 pandemic as negative HC. In some instances, reactive T-cells were detected in HC after MP stimulation, both on basis of T-cell activation and cytokine production. Since PBMC from these HC could not contain SARS-CoV-2-specific T-cells, we hypothesize that these responses were cross-reactive and had been induced by circulating seasonal 'common cold' coronaviruses. If we consider samples with a SI > 3 as responders, we identified 2 out of 10 HC (20%) to have these cross-reactive T-cells. This is in good accordance with a recent report on the presence of virusspecific CD4⁺ T-cells in COVID-19 patients, which reported the presence of SARS-CoV-2-reactive T-cells in 34% of the HC (Braun et al., 2020). The role of pre-existing SARS-CoV-2-reactive T-cells as a correlate of protection or pathology is unclear, and needs to be addressed in prospective studies.

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

Novel SARS-CoV-2 vaccines are currently in development and mainly focus on the surface glycoprotein S as an antigen for efficient induction of virus-specific neutralizing antibodies. We now show that S can also be a potent immunogen for inducing virus-specific CD4⁺ and CD8⁺ T-cells. Whether presence and certain phenotypes of T-cells are correlated to a 'good' or 'bad' prognosis remains to be determined. Collectively, these novel data are important for vaccine design and will facilitate the evaluation of future vaccine immunogenicity. **Author contributions** DW, AG, RLdS, AS and RDdV conceived and planned the experiments. DW. KSS. MPR, NMAO, RM and ECMvG contributed to sample preparation. DW, KSS, MPR, AG, NMAO, HE, JPCvsA, RM and RDdV carried out the experiments. DW, KSS, AG, MPGK, BLH, RLdS, AS and RDdV contributed to the interpretation of the results. RDdV took the lead in writing the manuscript, DW, KSS and RLdS contributed significantly. All authors provided critical feedback and helped shape the research, analysis and manuscript. **Acknowledgements** We thank all health care workers and laboratory personnel who contributed to treatment and diagnosis of these and other COVID-19 patients. Specifically, we thank Jeroen van Kampen, Corine Geurts van Kessel, Annemiek van der Eijk and Marshall Lammers for their contributions to these studies. This work has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreements No. 874735 (VEO) (MPGK, EvG and MPR).

Competing interest statement

269

270

272

The authors declare no competing interests.

Tables

		Activation (SI)			
		CD4+ T-cells		CD8+ T-cells	
	Paper ID	MP_S	MP_CD4_R	MP_S	MP_CD8
нс	HC_1	2.0	1.7	1.0	1.0
	HC_2	0.8	0.9	0.9	1.0
	HC_3	0.9	0.9	1.6	1.0
	HC_4	1.7	1.9	1.1	1.1
	HC_5	1.4	1.3	3.0	2.6
	HC_6	8.3	3.6	3.1	1.8
	HC_7	1.4	1.4	0.9	1.1
	HC_8	1.1	2.6	1.2	1.1
	HC_9	2.4	3.8	1.8	1.3
	HC_10	1.7	1.4	1.0	0.9
	total	1/10	2/10	1/10	0/10
COVID-19	Case 1	22.0	17.0	4.5	3.8
	Case 2	5.4	4.4	8.4	ND
	Case 3	33.4	18.9	6.7	1.5
	Case 4	29.8	12.6	4.5	3.4
	Case 5	123.3	43.0	1.0	1.1
	Case 6	28.2	5.4	48.0	2.5
	Case 7	57.4	58.8	3.2	5.8
	Case 8	28.6	23.0	1.7	1.2
	Case 9	25.2	3.5	3.7	1.5
	Case 10	18.9	14.4	25.8	15.8
	total	10/10	10/10	8/10	4/9

Table 1. Antigen-specific responses shown as stimulation index (SI) for HC and COVID-19 patients. Antigen-specific activation of CD4⁺ and CD8⁺ T-cells in COVID-19 patients after stimulation for 20 hours with peptide MegaPools (MP) shown as stimulation index (SI). SI is derived by dividing the percentage obtained with specific stimulation (MP) by the percentage obtained with the vehicle control (DMSO), values for respective stimulations are shown in Figure 2. Donors with a SI > 3 are regarded responders to MP stimulation, total responders per stimulation are shown at the bottom of the table. Non-responders (SI < 3) are shown in white background, responders are shown in shades of blue (darker blue equals a higher SI). HC = healthy control.

Figures




Figure 1. Clinical overview of moderate to severe COVID-19 ARDS patients. (a) Symptoms, hospitalization status, treatment and follow-up of n=10 COVID-19 ARDS patients included in this study. PBMC samples were obtained weekly after admission to the study. Symbols shown next to the cases match throughout all figures. (b) Flow cytometry performed on PBMC collected 14 days post inclusion showed that percentages CD3⁺ T-cells within the total LIVE gate were significantly lower in COVID-19 patients compared to healthy controls (HC), while (c) CD4:CD8 ratios were significantly higher. Panels b and c show individual values for n=10 patients versus n=10 HC, as well as the mean ± SD. Asterisk denotes a significant difference. HC = healthy control.




Figure 2. SARS-CoV-2-specific T-cell responses in COVID-19 ARDS patients. (a, b) Antigen-specific activation of CD4⁺ T-cells after stimulation for 20 hours with MP_S (a) and MP_CD4_R (b), measured via cell surface expression of CD69 and CD137 (gating in supplementary Figure 1). Two left panels show activation percentages (within CD3⁺CD4⁺ or CD3⁺CD8⁺ gate) obtained with the vehicle control (DMSO) and specific stimulation (MP) for HC and COVID-19 patients. The third panel shows the specific activation percentages corrected by subtracting the background present in the DMSO stimulation to allow comparison of both groups. The fourth panel shows the memory phenotype of the CD69⁺CD137⁺ responder cells in a donut diagram. (c, d) Similar layout to panels a and b. Antigen-specific activation of CD8⁺ T-cells after stimulation for 20 hours with MP_S (c) and MP_CD8 (d). Percentages from MP_CD8 stimulation are based on concatenated analysis of MP_CD8_A and MP_CD8_B, results obtained with separate stimulations are shown in supplementary Figure 2. Panels show individual values for n=10 patients versus n=10 HC, as well as the mean ± SD. Asterisk denotes a significant difference. HC = healthy control. Symbol shapes of COVID-19 patients are identical between panels, and refer back to figure 1.




Figure 3. SARS-CoV-2-specific cytokine production in COVID-19 ARDS patients. (a-j) Antigen-specific production of cytokines measured in cell culture supernatants from PBMC stimulated (20 hours) with MP_S. Two left panels show activation percentages obtained with the vehicle control (DMSO) and specific stimulation (MP) for HC and COVID-19 patients. The third panel shows the quantity corrected by subtracting the background present in the DMSO stimulation to allow comparison of both groups. Panels show individual values for n=10 patients versus n=10 HC, as well as the geometric mean. Asterisk denotes a significant difference. HC = healthy control. Additional cytokines (IL-4, IL17f and IL-21) are shown in supplementary Figure 3.






Figure 4. SARS-CoV-2 replication and humoral and cellular immune response kinetics in COVID-19 ARDS patients. (a, b, c) Sequential measurements of SARS-CoV-2 genomes detected in upper respiratory tract samples by real-time RT-PCR (40-ct, a), SARS-CoV-2-specific serum RBD IgG antibody levels detected by ELISA (OD450, b) and percentage SARS-CoV-2-specific CD4 $^+$ T-cells after MP_S stimulation of PBMC (c), plotted against days post onset of symptoms. Genome levels showed a significant decrease over time, antibody levels and specific T-cell frequencies significantly increased (p<0.001 for all three panels, ANOVA repeated measures). Panels show values for n=8 COVID-19 ARDS patients (case 1 – 8).

Supplementary Figures




Supplementary Figure 1. Flow cytometry gating strategy. (a-j) Gating strategy for detection of antigen-specific T-cells after stimulation of PBMC. (a) Live cells were selected, (b) followed by the selection of lymphocytes and (c) singlets. (d) CD3+ T-cells were gated and (e) divided into CD4+ and CD8+ T-cells. Both subsets were phenotyped as naïve (TN), central memory (TCM), effector memory (TEM) or terminally differentiated effectors (TEMRA) on basis of expression of CD45RA and CCR7 (f for CD4+ T-cells, g for CD8+ T-cells). (h-j) Within the different subsets, activated cells were identified via surface upregulation of activation induced markers CD69 and CD137. Percentages of CD69+CD137+ double positive cells, reflecting activated cells, were used for further analysis. Representative examples of DMSO (vehicle of the MP) (background control, h), CMV peptides (positive control, i) and a MP_S stimulation of PBMC from a COVID-19 patient.



Supplementary Figure 2. SARS-CoV-2-specific T-cell responses in COVID-19 ARDS patients.

(a, b) Antigen-specific activation of CD4* and CD8* T-cells in COVID-19 patients after stimulation for 20 hours with peptide MegaPools (MP) shown as stimulation index (SI). Stimulation index is derived by dividing the percentage obtained with specific stimulation (MP) by the percentage obtained with the vehicle control (DMSO), values for respective stimulations are shown in Figure 2. Donors with a SI > 3 (dotted line) are regarded responders to MP stimulation. (c, d) Antigen-specific activation of CD8* T-cells after stimulation for 20 hours with MP_CD8_A (c) and MP_CD8_B (d). The two left panels show activation percentages obtained with the vehicle control (DMSO) and specific stimulation (MP) for HC and COVID-19 patients. The third panel shows the specific activation percentages corrected by subtracting the background present in the DMSO stimulation to allow comparison of both groups. The fourth panel shows the stimulation index derived by dividing the percentage obtained with specific stimulation (MP) by the percentage obtained with the vehicle control (DMSO). Donors with a SI > 3 (dotted line) are regarded responders to MP stimulation. Panels show individual values for n=10 patients versus n=10 HC, as well as the mean ± SD. Asterisk denotes a significant difference. HC = healthy control.



Supplementary Figure 3. SARS-CoV-2-specific cytokine production in COVID-19 ARDS

366

367

368

369

370

371

372

373

patients. (a-c) Antigen-specific production of cytokines measured in cell culture supernatants from PBMC stimulated (20 hours) with MP S. Two left panels show activation percentages obtained with the vehicle control (DMSO) and specific stimulation (MP) for HC and COVID-19 patients. Third panel shows the quantity corrected by subtracting the background present in the DMSO stimulation to allow comparison of both groups. Panels show individual values for n=10 patients versus n=10 HC, as well as the geometric mean. Asterisk denotes a significant difference. HC = healthy control. (d) Antigenspecific production of cytokines per COVID-19 case. Circle diagrams represent the total amount of cytokines produced by the respective donor (corrected for DMSO background), quantities of different cytokines are shown as a percentage of whole. Clinical data for cases is described in Figure 1.

Methods

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

Ethical statement. Patients admitted into the intensive care unit (ICU) with Acute Respiratory Distress Syndrome (ARDS) resulting from SARS-CoV-2 infection at Erasmus MC, Rotterdam, the Netherlands were included in a biorepository study aimed at ARDS and sepsis in the ICU. The first EDTA blood samples for PBMC isolation were obtained no more than 2 days after admission into the Erasmus MC ICU until 21 days post inclusion for as long as the patient was in the ICU. Patient care and research were conducted in compliance within guidelines of the Erasmus MC and the Declaration of Helsinki. Due to the clinical state of most ARDS patients (i.e. intubated, comatose), deferred proxy consent was obtained instead of direct written informed consent from the patients themselves. Retrospective written informed consent was obtained from patients after recovery. The study protocol was approved by the medical ethical committee of Erasmus MC, Rotterdam, the Netherlands (MEC-2017-417 and MEC-2020-0222). For experiments involving healthy control human buffy coats, written informed consent for research use was obtained by the Sanguin Blood Bank (Rotterdam, the Netherlands). Diagnosis. Real-time RT-PCR on the E-gene was performed as described previously (Corman et al., 2020) on RNA isolated from sputa, nasopharyngeal or oropharyngeal swabs by MagnaPure (Roche diagnostics, The Netherlands) using the total nucleic acid (TNA) isolation kit. PBMC isolation. PBMC were isolated from EDTA blood samples. Tubes were centrifuged at 200g for 15 min to separate cellular parts. Plasma-containing fraction

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

was collected, centrifuged at 1200g for 15 minutes, plasma was aliquoted and stored at -20°C. The cellular fraction was reconstituted with phosphate-buffered saline (PBS) and subjected to Ficoll density gradient centrifugation (500g, 30min). PBMC were washed and frozen in 90% fetal bovine serum (FBS) and 10% dimethyl sulfoxide (DMSO, Sigma Life science) at -135°C. Upon use, PBMC were thawed in IMDM (Lonza, Belgium) supplemented with 10% FBS, 100 IU of penicillin/ml, 100 µg of streptomycin/ml (Lonza, Belgium) and 2 mM L-glutamine (Lonza, Belgium) (I10F medium). PBMC were treated with 50 U/ml benzonase (Merck) for 30min at 37°C prior to use in stimulation assays. Epitope MegaPool (MP) design and preparation. SARS-CoV-2 virus-specific CD4 and CD8 peptides were synthesized as crude material (A&A, San Diego, CA), resuspended in DMSO, pooled and sequentially lyophilized as previously reported(Carrasco Pro et al., 2015). SARS-CoV-2 epitopes were predicted using the protein sequences derived from the SARS-CoV-2 reference (GenBank: MN908947) and IEDB analysis-resource as previously described (Dhanda et al., 2019; Grifoni et al., 2020). Specifically, CD4 SARS-CoV-2 epitope prediction was carried out using a previously described approach in Tepitool resource in IEDB (Paul et al., 2015; Paul et al., 2016) similarly to what was previously described (Grifoni et al., 2020), but removing the resulting Spike glycoprotein epitopes from this prediction (CD4-R(remainder) MP, n=246). To investigate in depth Spike-specific CD4⁺ T-cells, overlapping 15-mer by 10 amino acids have been synthesized and pooled separately (CD-4 S(spike) MP, n=221). CD8 SARS-CoV-2 epitope prediction was performed as previously reported, using the NetMHCpan4.0 algorithm for the top 12 more frequent HLA alleles in the population (HLA-A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

A*11:01, HLA-A*23:01, HLA-A*24:02, HLA-B*07:02, HLA-B*08:01, HLA-B*35:01, HLA-B*40:01, HLA-B*44:02, HLA-B*44:03) and selecting the top 1 percentile predicted epitope per HLA allele (Grifoni et al., 2020). The 628 predicted CD8 epitopes were split in two CD8 MPs containing 314 peptides each. SARS-CoV-2 RBD ELISA. Serum or plasma samples were analyzed for the presence of SARS-CoV-2 specific antibody responses using a validated in-house SARS-CoV-2 receptor binding domain (RBD) IgG ELISA as previously described(Okba et al., 2020). Briefly, ELISA plates were coated with recombinant SARS-CoV-2 RBD protein. Following blocking, samples were added and incubated for 1 hour, after which the plates were washed and a secondary HRP-labelled rabbit anti-human IgG (DAKO) was added. Following a 1 hour incubation, the plates were washed, the signal was developed using TMB, and the OD₄₅₀ was measured for each well. All samples reported here were interrogated for the presence of antibodies on the same plate. Ex vivo stimulations. PBMC were plated in 96-wells U bottom plates at 1 x 106 PBMC per well in RPMI1640 (Lonza, Belgium) supplemented with 10% human serum, 100 IU of penicillin/ml, 100 µg of streptomycin/ml (Lonza, Belgium) and 2 mM L-glutamine (Lonza, Belgium) (R10H medium) and subsequently stimulated with the described CD4 and CD8 SARS-CoV-2 MPs at 1µg/ml. A stimulation with an equimolar amount of DMSO was performed as negative control, phytohemagglutinin (PHA, Roche, 1µg/ml) and stimulation with a combined CD4 and CD8 cytomegalovirus MP (CMV, 1µg/ml) were included as positive controls. Twenty hours after stimulation cells were stained for detection of activation induced markers and

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

subjected to flow cytometry. Supernatants were harvested for multiplex detection of cytokines. Flow cytometry. Activation-induced markers were quantified via flow cytometry (FACSLyric, BD Biosciences). A surface staining on PBMC was performed with anti-CD3^{PerCP} (BD, clone SK7), anti-CD4^{V450} (BD, clone L200), anti-CD8^{FITC} (DAKO, clone DK25), anti-CD45RAPE-Cy7 (BD, clone L48), anti-CCR7APC (R&D Systems, clone 150503), anti-CD69^{APC-H7} (BD, clone FN50) and anti-CD137^{PE} (Miltenyi, clone 4B4-1). T-cell subsets were identified via the following gating strategy: LIVE CD3⁺ were selected and divided in CD3⁺CD4⁺ and CD3⁺CD8⁺. Within the CD4 and CD8 subsets, memory subsets were gated as CD45RA+CCR7+ (naive, Tn), CD45RA-, CCR7⁺ (central memory, T^{CM}), CD45RA⁻CCR7⁻ (effector memory, T^{EM}) or CD45RA+CCR7- (terminally differentiated effectors, TEMRA). T-cells specifically activated by SARS-CoV-2 were identified by upregulation of CD69 and CD137. An average of 500,000 cells was always acquired, the gating strategy is schematically represented in (Supplementary Figure 1A-J). In analysis, PBMC stimulated with MP CD8 A and MP CD8 B were concatenated and analyzed as a single file for SARS-CoV-2-specific responses to MP CD8. **Multiplex detection of cytokines.** Cytokines in cell culture supernatants from ex vivo stimulations were quantified using a human Th cytokine panel (13-plex) kit (LEGENDplex, Biolegend). Briefly, cell culture supernatants were mixed with beads coated with capture antibodies specific for IL-5, IL-13, IL-2, IL-6, IL-9, IL-10, IFNy, TNF α , IL-17a, IL-17F, IL-4, IL-21 and IL-22 and incubated for 2 hours. Beads were washed and incubated with biotin-labelled detection antibodies for 1 hour, followed

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

by a final incubation with streptavidin PE. Beads were analyzed by flow cytometry. Analysis was performed using the LEGENDplex analysis software v8.0, which distinguishes between the 13 different analytes on basis of bead size and internal dye. Quantity of each respective cytokine is calculated on basis of intensity of the streptavidin^{PE} signal and a freshly prepared standard curve. **Statistical analysis.** For comparison of CD3⁺ T-cell percentages, CD4:CD8 ratios, CD69⁺CD137⁺ stimulated T-cells and cytokine levels between HC and COVID-19 patients all log transformed data was tested for normal distribution. If distributed normally, groups were compared via an unpaired T test. If not distributed normally, groups were compared via a Mann-Whitney test. Comparisons between different stimulations (DMSO versus MP) were performed by paired T-test (normal distribution) or Wilcoxon rank test (no normal distribution). Two-tailed p values are reported throughout the manuscript. One way ANOVA repeated measures was used to test for increasing or decreasing trends over sequential time points (0, 7 and 14 days post inclusion).

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

References

Braun, J., L. Loyal, M. Frentsch, D. Wendisch, P. Georg, F. Kurth, S. Hippenstiel, M. Dingeldey, B. Kruse, F. Fauchere, E. Baysal, M. Mangold, L. Henze, R. Lauster, M. Mall, K. Beyer, J. Roehmel, J. Schmitz, S. Miltenyi, M.A. Mueller, M. Witzenrath, N. Suttorp, F. Kern, U. Reimer, H. Wenschuh, C. Drosten, V.M. Corman, C. Giesecke-Thiel, L.-E. Sander, and A. Thiel. 2020. Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. Carrasco Pro, S., J. Sidney, S. Paul, C. Lindestam Arlehamn, D. Weiskopf, B. Peters, and A. Sette. 2015. Automatic Generation of Validated Specific Epitope Sets. J Immunol Res 2015:763461. Chan, J.F., S. Yuan, K.H. Kok, K.K. To, H. Chu, J. Yang, F. Xing, J. Liu, C.C. Yip, R.W. Poon, H.W. Tsoi, S.K. Lo, K.H. Chan, V.K. Poon, W.M. Chan, J.D. Ip, J.P. Cai, V.C. Cheng, H. Chen, C.K. Hui, and K.Y. Yuen. 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395:514-523. Chen, G., D. Wu, W. Guo, Y. Cao, D. Huang, H. Wang, T. Wang, X. Zhang, H. Chen, H. Yu, X. Zhang, M. Zhang, S. Wu, J. Song, T. Chen, M. Han, S. Li, X. Luo, J. Zhao, and Q. Ning. 2020. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130:2620-2629. Corman, V.M., O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D.K. Chu, T. Bleicker, S. Brunink, J. Schneider, M.L. Schmidt, D.G. Mulders, B.L. Haagmans, B. van der Veer, S. van den Brink, L. Wijsman, G. Goderski, J.L. Romette, J. Ellis, M. Zambon, M. Peiris, H. Goossens, C. Reusken, M.P. Koopmans, and C.

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

Drosten. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 25: Dhanda, S.K., S. Mahajan, S. Paul, Z. Yan, H. Kim, M.C. Jespersen, V. Jurtz, M. Andreatta, J.A. Greenbaum, P. Marcatili, A. Sette, M. Nielsen, and B. Peters. 2019. IEDB-AR: immune epitope database-analysis resource in 2019. Nucleic Acids Res 47:W502-W506. Grifoni, A., J. Sidney, Y. Zhang, R.H. Scheuermann, B. Peters, and A. Sette. 2020. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Cell Host Microbe 27:671-680 e672. Herold, T., V. Jurinovic, C. Arnreich, J.C. Hellmuth, M. von Bergwelt-Baildon, M. Klein, and T. Weinberger. 2020. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. MedRxiv Huang, C., Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, and B. Cao. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497-506. Kissler, S.M., C. Tedijanto, E. Goldstein, Y.H. Grad, and M. Lipsitch. 2020. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science Li, C.K., H. Wu, H. Yan, S. Ma, L. Wang, M. Zhang, X. Tang, N.J. Temperton, R.A. Weiss, J.M. Brenchley, D.C. Douek, J. Mongkolsapaya, B.H. Tran, C.L. Lin, G.R. Screaton, J.L. Hou, A.J. McMichael, and X.N. Xu. 2008. T cell responses to whole SARS coronavirus in humans. J Immunol 181:5490-5500.

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

Mahnke, Y.D., T.M. Brodie, F. Sallusto, M. Roederer, and E. Lugli. 2013. The who's who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol 43:2797-2809. Mehta, P., D.F. McAuley, M. Brown, E. Sanchez, R.S. Tattersall, J.J. Manson, and U.K. Hlh Across Speciality Collaboration. 2020. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 395:1033-1034. Ni, L., F. Ye, M.-L. Cheng, Y. Feng, Y.-Q. Deng, H. Zhao, P. Wei, J. Ge, M. Gou, X. Li, L. Sun, T. Cao, P. Wang, C. Zhou, R. Zhang, P. Liang, H. Guo, X. Wang, C.-F. Qin, F. Chen, and C. Dong. 2020. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. *Immunity* Okba, N.M.A., M.A. Muller, W. Li, C. Wang, C.H. GeurtsvanKessel, V.M. Corman, M.M. Lamers, R.S. Sikkema, E. de Bruin, F.D. Chandler, Y. Yazdanpanah, Q. Le Hingrat, D. Descamps, N. Houhou-Fidouh, C. Reusken, B.J. Bosch, C. Drosten, M.P.G. Koopmans, and B.L. Haagmans. 2020. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients. Emerg Infect Dis 26: Paul, S., C.S. Lindestam Arlehamn, T.J. Scriba, M.B. Dillon, C. Oseroff, D. Hinz, D.M. McKinney, S. Carrasco Pro, J. Sidney, B. Peters, and A. Sette. 2015. Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. J Immunol Methods 422:28-34. Paul, S., J. Sidney, A. Sette, and B. Peters. 2016. TepiTool: A Pipeline for Computational Prediction of T Cell Epitope Candidates. Curr Protoc Immunol 114:18 19 11-18 19 24.

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* 401:708-712. Thevarajan, I., T.H.O. Nguyen, M. Koutsakos, J. Druce, L. Caly, C.E. van de Sandt, X. Jia, S. Nicholson, M. Catton, B. Cowie, S.Y.C. Tong, S.R. Lewin, and K. Kedzierska. 2020. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med 26:453-455. Wang, Z., A. Zhang, Y. Wan, X. Liu, C. Qiu, X. Xi, Y. Ren, J. Wang, Y. Dong, M. Bao, L. Li, M. Zhou, S. Yuan, J. Sun, Z. Zhu, L. Chen, Q. Li, Z. Zhang, X. Zhang, S. Lu, P.C. Doherty, K. Kedzierska, and J. Xu. 2014. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci U S A 111:769-774. Xu, Z., L. Shi, Y. Wang, J. Zhang, L. Huang, C. Zhang, S. Liu, P. Zhao, H. Liu, L. Zhu, Y. Tai, C. Bai, T. Gao, J. Song, P. Xia, J. Dong, J. Zhao, and F.S. Wang. 2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8:420-422. Zhao, J., A.N. Alshukairi, S.A. Baharoon, W.A. Ahmed, A.A. Bokhari, A.M. Nehdi, L.A. Laygah, M.G. Alghamdi, M.M. Al Gethamy, A.M. Dada, I. Khalid, M. Boujelal, S.M. Al Johani, L. Vogel, K. Subbarao, A. Mangalam, C. Wu, P. Ten Eyck, S. Perlman, and J. Zhao. 2017. Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci Immunol 2: eaan5393.